Multiple Myeloma Posts - Page 22 of 27 on Medivizor

Looking for patients with relapsed or refractory multiple myeloma to test the safety and effectiveness of genetically engineered T-cells alone or with immunotherapy

$Looking for patients with relapsed or refractory multiple myeloma to test the safety and effectiveness of genetically engineered T-cells alone or with immunotherapy$

Posted by Medivizor on Sep 26, 2017 in Multiple Myeloma | 0 comments

In a nutshell This early phase 1 clinical trial will test the safety and effectiveness of genetically engineered NY-ESO-1 specific (c259) T-cells cells with or without pembrolizumab (Keytruda) in treating relapsed or refractory (unresponsive to treatment) multiple myeloma. The details NY-ESO-1 is a protein found on many types of cancer cells...

Searching for patients with high-risk smoldering multiple myeloma to test the effectiveness of an immunotherapy

Posted by Medivizor on Sep 26, 2017 in Multiple Myeloma | 0 comments

In a nutshell This phase 2 clinical trial will test the effectiveness of isatuximab (SAR650984) in patients with high-risk smoldering multiple myeloma. The primary outcome will be measured by the overall response. This trial is being conducted at Mount Sinai Hospital and Memorial Sloan Kettering Cancer Center in New York, New York, as well as...

Carfilzomib versus bortezomib in multiple myeloma that has not responded to treatment

Posted by Medivizor on Sep 23, 2017 in Multiple Myeloma | 0 comments

In a nutshell This paper compared the use of carfilzomib (Kyprolis) and bortezomib (Velcade) in the treatment of multiple myeloma. This study concluded that carfilzomib was associated with a reduced risk of death compared with bortezomib. Some background Multiple myeloma is a cancer of the plasma cells. New treatments have led to longer survival...

Is There a Difference in Treatment in Smoldering vs. Active Myeloma?

Posted by Medivizor on Sep 14, 2017 in Multiple Myeloma | 0 comments

In this Patient Power replay, an expert panel discusses the differences in treatment between smoldering and active myeloma. The expert panel includes Host Andrew Schorr, Dr. Larry Anderson, Jr. of UT Southwest Medical Center, Dr. Robert Orlowski of MD Anderson Cancer Center, and patient advocate Lynette Heniff. In this video, the panel discusses risk...

Treatment options and combinations for multiple myeloma

Posted by Medivizor on Sep 14, 2017 in Multiple Myeloma | 0 comments

In a nutshell The aim of this study was to review current treatment options and combinations for multiple myeloma. Some background Advances in first-line treatments have improved response and survival rates among multiple myeloma patients. In recent years immunotherapies and targeted therapies have become a major treatment option....

Examining infection rates after stem cell transplantation

Posted by Medivizor on Sep 4, 2017 in Multiple Myeloma | 0 comments

In a nutshell This study examined infection rates after autologous stem cell transplantation in multiple myeloma patients. 1.2% in-hospital deaths were recorded in this study. All were caused by an infection following the stem cell transplant. Some background Autologous stem cell transplantation after high-dose chemotherapy has resulted in...

Looking for patients with multiple myeloma to test the effectiveness of a combination therapy post autologous stem cell transplantation

Posted by Medivizor on Sep 2, 2017 in Multiple Myeloma | 0 comments

In a nutshell This phase 2 clinical trial will test the effectiveness of IRD, a combination therapy of ixazomib, lenalidomide, and dexamethasone, after stem cell transplantation, followed by ixazomib or lenalidomide as a maintenance therapy in treating multiple myeloma. The primary outcome will be measured by the disease improvement. The details...

Looking for patients with relapsed or refractory multiple myeloma to test the effectiveness of a combination chemotherapy prior to autologous stem cell transplantation

$Looking for patients with relapsed or refractory multiple myeloma to test the effectiveness of a combination chemotherapy prior to autologous stem cell transplantation$

Posted by Medivizor on Sep 2, 2017 in Multiple Myeloma | 0 comments

In a nutshell This phase 2 clinical trial will test the effectiveness of a combination of panobinostat (Farydak), gemcitabine (Gemzar), busulfan (Busulfex), and melphalan (Alkeran), and a stem cell transplant in treating multiple myeloma. The primary outcome will be measured by the time until the disease progresses. This trial is being conducted in...

A look at frailty in elderly multiple myeloma patients

Posted by Medivizor on Aug 26, 2017 in Multiple Myeloma | 0 comments

In a nutshell This study reviewed evidence on how to categorize older multiple myeloma patients. Some background Advances in treatment approaches have improved response rates and survival for multiple myeloma patients. These typically involve combining immunotherapies, such as lenalidomide (Revlimid), with proteasome inhibitors, such as bortezomib...

Bortezomib does not increase cardiac risk in multiple myeloma

Posted by Medivizor on Aug 21, 2017 in Multiple Myeloma | 0 comments

In a nutshell This study analyzed the results of multiple studies to examine the effect of bortezomib (Velcade) on cardiac risk (heart health) in multiple myeloma. Results showed no effect on cardiac risk with bortezomib-based treatment. The incidence of cardiac events was low across all treatment groups. Some background Many multiple myeloma...

FDA News Releases and Signing Up for Alerts

Posted by Kathleen Hoffman on Aug 13, 2017 in Benign prostatic hyperplasia, Blog, Breast cancer, Colorectal cancer, Coronary artery disease, Diabetes mellitus, Erectile dysfunction, Hodgkin's lymphoma, Hypertension, Infertility, Kidney stones, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer, Rheumatoid Arthritis, Stroke, Urinary incontinence, Urinary tract infection | 1 comment

You may not know this but you can get warnings from the FDA on problems with prescription medications and over-the-counter drugs. For example, on August 11, a FDA News Release issued this warning about over-the-counter liquid vitamins that are given to young children and those who cannot swallow pills. “The U.S. Food and Drug Administration is...

Combining carfilzomib with cyclophosphamide and dexamethasone for newly diagnosed multiple myeloma

Posted by Medivizor on Aug 7, 2017 in Multiple Myeloma | 0 comments

In a nutshell This study examined the safety of combining carfilzomib (Kyprolis), cyclophosphamide (Cytoxan), and dexamethasone Decadron) for multiple myeloma. Researchers reported early results on the safety and potential effectiveness of this treatment combination. Some background Advances in first-line treatments have improved response and...

Multiple Myeloma Posts on Medivizor

Looking for patients with relapsed or refractory multiple myeloma to test the safety and effectiveness of genetically engineered T-cells alone or with immunotherapy

Searching for patients with high-risk smoldering multiple myeloma to test the effectiveness of an immunotherapy

Carfilzomib versus bortezomib in multiple myeloma that has not responded to treatment

Is There a Difference in Treatment in Smoldering vs. Active Myeloma?

Treatment options and combinations for multiple myeloma

Examining infection rates after stem cell transplantation

Looking for patients with multiple myeloma to test the effectiveness of a combination therapy post autologous stem cell transplantation

Looking for patients with relapsed or refractory multiple myeloma to test the effectiveness of a combination chemotherapy prior to autologous stem cell transplantation

A look at frailty in elderly multiple myeloma patients

Bortezomib does not increase cardiac risk in multiple myeloma

FDA News Releases and Signing Up for Alerts

Combining carfilzomib with cyclophosphamide and dexamethasone for newly diagnosed multiple myeloma

Categories

Recent Posts

Archives

Multiple Myeloma Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email